Non-Inferiority 'Mistake' Hits E-Therapeutics' Depression Ambition
This article was originally published in Scrip
"Our mistake was to structure the trial as a non-inferiority to amitriptyline study," e-Therapeutics CEO Malcolm Young told Scrip. "We should have called it a 'dose-ranging' study – which is what it was." The company saw its share price plummet on Feb. 15 following top-line results from its Phase IIb trial of ETS6103 (a controlled-release formulation of the analgesic tramadol) in major depressive disorder, which failed to meet its efficacy endpoint of establishing non-inferiority when compared to amitriptyline.
You may also be interested in...
Dr Raymond Barlow, the newly appointed CEO of e-Therapeutics, is hoping he can turn the lackluster business around and reposition it as a show stealing co-star for efficient drug discovery partnering, utilizing its bioinformatics platform technology.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.